Warren Krutchick DDS      
287 Center Road = West Seneca = NY 14224 = 716 675-9225
 


 

In our continuing efforts to provide the most advanced technology and highest quality care available to our patients, this practice is proud to announce the inclusion to the ViziLite exam as an integral part of our annual comprehensive oral cancer screening.

One person dies every hour from oral cancer in the Unites States - and the mortality has remained unchanged for more than 40 years.  Alarmingly, more than 25% of oral cancer victims have no lifestyle risk factors.  Clinical studies have determined that using ViziLite after the standard oral cancer examination improves the clinician's ability to identify, evaluate and monitor suspicious areas at their earliest stages. Early detection of pre-cancerous tissue can minimize or eliminate the potentially disfiguring effects of oral cancer and possibly save your life.  Proven screening technologies such as mammogram, Pap smear, PSA and colonoscopy offer the same types of early detection of cancer. ViziLite is an easy and painless examination that gives this practice the best chance to find any oral abnormalities you may have at the earliest possible stage. This technology is the only FDA-cleared device for the indentification and monitoring of oral abnormalities that could lead to cancer.

Oral cancer risk by patient profile is listed below:

Highest Risk:  Patients age 40 and older and lifestyle risk factors (tobacco use); patients with a history of oral cancer

High Risk: Patients age 40 and older; tobacco users of any age

Increased Risk: Patients age 18 - 39

Dental Insurance might not cover this advanced oral cancer screening as an addition to the standard visual examination.  This practice prescribes the ViziLite exam for all patients at increased risk, high risk and highest risk for oral cancer (adult patients age 18 and older and tobacco users of any age).  We will be performing the ViziLite exam following the standard oral cancer examination of the oral cavity for a fee.

ViziLite® Plus oral lesion identification and marking system The newest tool in the fight against oral disease is the ViziLite® Plus oral lesion identification and marking system. ViziLite® Plus, from Zila Pharmaceuticals, combines the oral screening technology of ViziLite, an advanced chemiluminescent light technology to help detect oral abnormalities, with TBlue630™. TBlue630 is the only patented pharmaceutical-grade form of toluidine blue that has been cleared by the FDA for use in marking lesions identified during a ViziLite examination. ViziLite Plus makes oral screening more comprehensive than ever before and is indicated for use in individuals at increased risk of oral cancer. If ViziLite reveals an abnormality, TBlue630 can be used to mark suspicious lesions for further evaluation.

For more information about Zila, visit www.zila.com

Click here to view the Vizilite Brochure

ViziLite® Plus
In West Seneca New York and the surrounding
Buffalo - Orchard Park - East Aurora - Amherst NY areas.